Dominika Raźniewska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dominika Raźniewska has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Radecka
Department of Oncology, Institute of Medical Sciences, University of Opole, 45-052 Opole, Poland
1 shared publication - Magdalena Grabiec
Department of Clinical Oncology, Medical University of Lodz, 92-231 Lodz, Poland
1 shared publication - Magdalena Krakowska
Department of Clinical Oncology, Medical University of Lodz, 92-231 Lodz, Poland
1 shared publication - Piotr Potemski
Department of Chemotherapy, Medical University of Lodz, Copernicus Memorial Hospital of Lodz, 90-549 Lodz, Poland
1 shared publication - Tadeusz Kałużewski
Department of Genetics, Polish Mother’s Memorial Hospital Research Institute, 93-338 Lodz, Poland
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 332
Retrospective Analysis of Regorafenib Efficiency in Treatment of Metastatic Colorectal Cancer—Experience of Two Polish Comprehensive Cancer Centers
Objectives: Colorectal cancer is a major public health concern, ranking third in incidence among all malignant tumors both in Poland and globally. We conducted a retrospective study to evaluate the effectiveness of regorafenib in patients with metastatic colorectal cancer ineligible for local therapy treated at two Polish comprehensive cancer centers between 2021 and 2024. Methods: The analysis included 29 patients who had previously received all standard therapies: fluoropyrimidines, oxaliplatin, and irinotecan (in a multi-agent regimen or sequentially) and bevacizumab (anti-VEGF therapy). In patients with tumors negative for KRAS, NRAS and BRAF mutations, cetuximab or panitumumab (anti-EGFR therapy) were also used. Results: The median progression-free survival (PFS) was 2.5 months, and the median overall survival (OS) was 5.8 months. Disease stabilization was observed in five patients, with a median duration of 5.6 months, and no partial or complete remission were recorded. Conclusions: Our results were similar to those of the phase III CORRECT trial, which established the clinical utility of regorafenib. Only minor differences in survival outcomes were noted—likely due to real-world variability in patient characteristics and timing of treatment assessments. However, continued investigation of personalized and sequential treatment strategies that contain anti-angiogenic drugs is warranted to optimize outcomes.
- 1 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 332
Open AccessRetrospective Analysis of Regorafenib Efficiency in Treatment of Metastatic Colorectal Cancer—Experience of Two Polish Comprehensive Cancer Centers
Objectives: Colorectal cancer is a major public health concern, ranking third in incidence among all malignant tumors both in Poland and globally. We conducted a retrospective study to evaluate the effectiveness of regorafenib in patients with metastatic colorectal cancer ineligible for local therapy treated at two Polish comprehensive cancer centers between 2021 and 2024. Methods: The analysis included 29 patients who had previously received all standard therapies: fluoropyrimidines, oxaliplatin, and irinotecan (in a multi-agent regimen or sequentially) and bevacizumab (anti-VEGF therapy). In patients with tumors negative for KRAS, NRAS and BRAF mutations, cetuximab or panitumumab (anti-EGFR therapy) were also used. Results: The median progression-free survival (PFS) was 2.5 months, and the median overall survival (OS) was 5.8 months. Disease stabilization was observed in five patients, with a median duration of 5.6 months, and no partial or complete remission were recorded. Conclusions: Our results were similar to those of the phase III CORRECT trial, which established the clinical utility of regorafenib. Only minor differences in survival outcomes were noted—likely due to real-world variability in patient characteristics and timing of treatment assessments. However, continued investigation of personalized and sequential treatment strategies that contain anti-angiogenic drugs is warranted to optimize outcomes.